MedTrace Logo

Perillyl Alcohol in Treating Patients With Metastatic Breast Cancer

NCT00003219 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-12-13

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of perillyl alcohol in treating patients with metastatic breast cancer that has not responded to previous chemotherapy.

Conditions

Interventions

DRUG

perillyl alcohol

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Howard H. Bailey, MD · University of Wisconsin, Madison

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-05-31
Primary Completion
1998-05-31
Completion
1998-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003219 on ClinicalTrials.gov